Contact Pharma Staff04.28.20
Stevanato Group, a producer of glass primary packaging and provider of integrated capabilities for combination products, and Cambridge Design Partnership (CDP), a UK- and U.S-based technology and product design partner, are collaborating to develop a new pen-injector based on the Axis-D technology and intellectual property (IP) licensed exclusively from Haselmeier in 2019.
The agreement leverages CDP’s design and development expertise in drug delivery devices, as well as Stevanato Group’s experience in glass containers, tooling, injection molding, device assembly and its global commercial network.
CDP and Stevanato Group will work together from the first concept right through design development, scale-up, regulatory submission, and commercial-scale production in all global markets. The collaboration supports Stevanato Group’s portfolio expansion of devices for patients suffering from diabetes.
“We are delighted to be announcing this partnership,” said Uri Baruch, CDP’s head of drug delivery. “Stevanato Group is well-established in the device field as a leading supplier of cartridges and assembly equipment for pen-injectors. It is a pleasure to extend our existing working relationship with them for their pen-injector and to address the needs of patients.”
The agreement leverages CDP’s design and development expertise in drug delivery devices, as well as Stevanato Group’s experience in glass containers, tooling, injection molding, device assembly and its global commercial network.
CDP and Stevanato Group will work together from the first concept right through design development, scale-up, regulatory submission, and commercial-scale production in all global markets. The collaboration supports Stevanato Group’s portfolio expansion of devices for patients suffering from diabetes.
“We are delighted to be announcing this partnership,” said Uri Baruch, CDP’s head of drug delivery. “Stevanato Group is well-established in the device field as a leading supplier of cartridges and assembly equipment for pen-injectors. It is a pleasure to extend our existing working relationship with them for their pen-injector and to address the needs of patients.”
